Dr Roy Maute (Pheast Therapeutics)
ArticleThe potential of CD24 in cancer immunotherapy
Cofounder & Chief Scientific Officer of Pheast Therapeutics, Dr Roy Maute, reveals his company’s promising drug candidate and explains why they have focused on their chosen target.